Last update 29 Mar 2025

Iboctadekin

Overview

Basic Info

Drug Type
Interleukins
Synonyms
Iboctadekin (USAN/INN), Interleukin-18 (GSK), Recombinant human interleukin-18
+ [4]
Target
Action
agonists
Mechanism
IL18R1 agonists(Interleukin 18 receptor agonists)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhasePendingPhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D04487--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic melanomaPhase 2
United States
15 Nov 2004
Metastatic melanomaPhase 2
Australia
15 Nov 2004
CD20 positive B-Cell LymphomaPhase 1
United States
31 Jul 2007
Advanced Malignant Solid NeoplasmPhase 1
United States
01 Apr 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(MS patients)
djfywzddbj(sgtinadive) = cngacexcij ciqhtelfws (ylqvkrbxgd )
Positive
09 Sep 2014
(Healthy donors)
djfywzddbj(sgtinadive) = ltclgowzwm ciqhtelfws (ylqvkrbxgd )
Phase 1
16
xqzavdrvcg(stbzgelfyp) = 6% uixxwronck (xhwhjaplhk )
-
20 May 2012
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free